Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenshen Yiqi is a traditional Chinese medicine (TCM) compound prescription commonly formulated as granules or "keli" (granulated extract). It is primarily used for the treatment of chronic obstructive pulmonary disease (COPD), especially in patients diagnosed with lung and kidney qi deficiency according to TCM principles. The formulation contains multiple herbal ingredients whose precise composition may vary by manufacturer but typically aims to tonify the kidney and supplement qi. Mechanistically, preclinical studies suggest that it alleviates airway inflammation and remodeling by modulating molecular pathways such as the long noncoding RNA-XIST/microRNA-200c-3p axis and the miR-155/FoxO3a axis. These actions result in reduced proliferation and migration of human airway smooth muscle cells exposed to cigarette smoke extract, potentially through upregulation of cell cycle inhibitors (p21, p27) and FoxO3a while downregulating proliferative markers (PCNA, Ki67)[1][2][3][4][10]. Clinical trials are ongoing for COPD; other experimental models have explored its effects on severe pneumonia[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wenshen Yiqi.